Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
10 reasons why gold is a good buy in 2025 – CNBC TV18
10 reasons why gold is a good buy in 2025 – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday

Tag: Glenmark Pharmaceuticals Q3 numbers

Markets
Sarvesh Gautam

Glenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues – CNBC TV18

[ad_1] Glenmark Pharmaceuticals Ltd on Friday (February 14) reported a net profit of ₹347.9 crore for Q3FY25, recovering from a net loss of ₹351.3 crore. Company Value Change %Change Revenue from operations surged 35.1% to ₹3,387.6 crore against ₹2,506.7 crore in the corresponding period of the preceding fiscal. At the operating level, EBITDA zoomed to […]

Back To Top
Translate »